99mTc-NC100692 — a tracer for imaging vitronectin receptors associated with angiogenesis: a preclinical investigation

Edwards, David S.; Jones, Paul A.; Haramis, H.; Battle, Mark; Lear, Rochelle; Barnett, D. Jon; Edwards, Catherine; Crawford, Hazel; Black, Andrew; Godden, Vanessa

doi:10.1016/j.nucmedbio.2007.11.010

Cited by 27 publications

(26 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…9B) [228], a small peptide with high affinity for integrin receptors [235,236]. Twenty patients (sixteen with suggestive mammographic findings and four with benign lesions) each received about 20 mCi of 99m Tc-NC100692.…”

Section: Clinical Imaging Of Integrin Vmentioning

confidence: 99%

Imaging of Integrins as Biomarkers for Tumor Angiogenesis

Cai¹,

Niu²,

Chen³

2008

CPD

166

161

View full text Add to dashboard Cite

The integrin family plays important roles during tumor angiogenesis, the formation of new blood vessels from pre-existing vasculature. Traditional structural and functional imaging techniques are not sufficient for early lesion detection, patient stratification, or monitoring the therapeutic efficacy against cancer. Molecular imaging, the visualization, characterization and measurement of biological processes at the molecular and cellular levels in humans and other living systems, can fulfill these goals. In this review article, we will summarize the current state-of-the-art of imaging integrin (alpha(2)beta(1), alpha(3)beta(1), alpha(4)beta(1), alpha(v)beta(3), and alpha(v)beta(6)) expression using either single molecular imaging modality (magnetic resonance imaging, ultrasound, optical, single photon emission computed tomography, and positron emission tomography) or a combination of different modalities. For clinical translation, radionuclide-based imaging will have broad potential applications in cancer patients and the currently available clinical data (exclusively on integrin alpha(v)beta(3) so far) will be discussed in detail. The design, optimization, and characterization of imaging agents targeting integrins will be presented and areas needing extensive future research effort will be discussed. In the new era of personalized medicine, fast clinical translation and incorporation of integrin imaging into anti-cancer clinical trials will be critical for the maximum benefit of cancer patients.

show abstract

Section: Clinical Imaging Of Integrin Vmentioning

confidence: 99%

Imaging of Integrins as Biomarkers for Tumor Angiogenesis

Cai¹,

Niu²,

Chen³

2008

CPD

166

161

View full text Add to dashboard Cite

show abstract

“…60 Other researchers have reported the use of 99m Tclabeled tracers containing the RGD motif for noninvasive imaging of angiogenesis in various animal models. [61][62][63][64] The 99m Tc labeled peptide, 99m TcNC100692, has a high affinity for the αvβ3 integrins, is metabo lically stable, and has a biodistribution favorable for in vivo imaging purposes. 62 Hua et al demon strated the potential of 99m TcNC100692 for targeted imaging of angiogenesis in a murine model of peripheral angiogenesis using highresolution pinhole planar and microSPECT imaging.…”

Section: Neuroreceptor Imagingmentioning

confidence: 99%

“…[61][62][63][64] The 99m Tc labeled peptide, 99m TcNC100692, has a high affinity for the αvβ3 integrins, is metabo lically stable, and has a biodistribution favorable for in vivo imaging purposes. 62 Hua et al demon strated the potential of 99m TcNC100692 for targeted imaging of angiogenesis in a murine model of peripheral angiogenesis using highresolution pinhole planar and microSPECT imaging. 65 The same imaging strategy was used to assess myo cardial angiogenesis in mice lacking the gene for matrix metallo proteinase9 (MMP9).…”

Section: Neuroreceptor Imagingmentioning

confidence: 99%

PET and SPECT in cardiovascular molecular imaging

2009

View full text Add to dashboard Cite

The current focus of cardiovascular medicine is on early detection and prevention of disease, to control the escalating costs of health care. To achieve this goal, novel imaging approaches that allow for early detection of disease and risk stratification are needed. Traditionally, the diagnosis, monitoring, and prognostication of cardiovascular disease were based on techniques that measured changes in metabolism, blood flow, and biological function. Molecular imaging is emerging as a new tool for the noninvasive detection of biological processes that can differentiate and characterize tissues before manifestation of gross anatomical features or physiological consequences. Leading the way are techniques involving high-sensitivity radiotracers that could revolutionize current diagnostic paradigms. This Review provides an overview of selected molecular-based single photon emission CT (SPECT) and PET imaging strategies for the evaluation of cardiovascular disease-including the evaluation of myocardial metabolism and neurohumoral activity of the heart-and potential future targeted methods of evaluating critical molecular processes, such as atherosclerosis, ventricular remodeling after myocardial infarction, and ischemia-associated angiogenesis.

show abstract

“…percentages of injected dose of 99m Tc-NC100692 in the liver (5.03±0.64%) and kidneys (4.52±1.03%)[32] are significantly higher than those of 99m Tc-EDDA/HYNIC-E-[c(RGDfK)] 2 (liver = 1.98±0.26% ID/g or 2.20±0.31 ID/organ; kidneys = 4.63±0.56% ID/g or 1.76±0.22 ID/ organ).…”

mentioning

confidence: 99%

Kit preparation and biokinetics in women of 99mTc-EDDA/HYNIC-E-[c(RGDfK)]2 for breast cancer imaging

Ortiz-Arzate

Santos-Cuevas

Ocampo‐García

et al. 2014

Nuclear Medicine Communications

View full text Add to dashboard Cite

All absorbed doses were comparable to those known from most of the (99m)Tc studies. (99m)Tc-EDDA/HYNIC-E-[c(RGDfK)]2 obtained from kit formulations showed high tumour uptake in patients with malignant lesions, making it a promising imaging radiopharmaceutical for targeting site-specific breast cancer. The results obtained in this study warrant further clinical studies to determine the specificity and sensitivity of (99m)Tc-EDDA/HYNIC-E-[c(RGDfK)]2.

show abstract

99mTc-NC100692 — a tracer for imaging vitronectin receptors associated with angiogenesis: a preclinical investigation

Cited by 27 publications

References 24 publications

Imaging of Integrins as Biomarkers for Tumor Angiogenesis

Imaging of Integrins as Biomarkers for Tumor Angiogenesis

PET and SPECT in cardiovascular molecular imaging

Kit preparation and biokinetics in women of 99mTc-EDDA/HYNIC-E-[c(RGDfK)]2 for breast cancer imaging

Contact Info

Product

Resources

About